Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) has posted mixed results for the first quarter of 2022, as earnings surpassed but revenue missed estimates. Shares of the company rose almost 3.5% to close at $183.78 in Monday’s extended trading session. Revenue & Earnings Revenues for the quarter stood at $23.4 billion, up 5% from the same quarter last year. The growth in revenues was primarily driven by the 6.3% and 5.9% year-over-year rise witnessed in the Pharmaceutical and MedTech segments, respectively. Further, the revenue figure failed to meet the consensus estimate of $23.67 billion. Earnings per share (EPS) for the quarter rose 3.1% year-over-year to $2.
https://www.tipranks.com/news/johnson-johnson-rises-despite-mixed-q1-numbers?utm_source=advfn.com&utm_medium=referral